drugset / Trial / NCT00588835

Pharmacokinetic Study on the Addition of Aprepitant to Cisplatin - Etoposide Treatment in Lung Cancer Patients

NCT00588835

RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to determine whether aprepitant can be used in the Cisplatin - Etoposide chemotherapeutic regimen.

Timeline

Start
2008-03
Primary completion
2010-01
Completion
2010-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Aprepitant Other / unclassified 80 mg Oral
Comparator Dexamethasone Small molecule
Comparator Ondansetron Other / unclassified

Indications